The U.S. Food and Drug Administration (“FDA”) announced the launch of its “Green List” initiative designed to protect consumers from illegally imported GLP-1 drug ingredients—such as semaglutide and ...
On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results